AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical